

Paris, France, 7th July 2026.

A New Chapter for Ariana Pharma: Thomas Turcat appointed as Chief Executive Officer.

Ariana Pharma, the explainable AI company, today announced the appointment of **Thomas Turcat** as **Chief Executive Officer**.

The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise to transform small, heterogeneous clinical cohorts into regulatory-ready results leveraging Thomas' broad commercial expertise. The output is transparent and explainable, giving research teams evidence they can understand, challenge, and act on.

Delivered as a team-as-a-service, Ariana Pharma works alongside biotech partners from pre-clinical through Phase II to turn limited, complex data into decisions that move programs forward. At the heart of this approach is KEM[®], the company's explainable AI (eXp-AI) platform, which applies rule-association-based logic to surface clear, actionable insights from small and heterogeneous cohorts. This technology enabled a long and successful track-record and recognized expertise by Health Authorities in the United States and Europe.

Thomas Turcat brings more than 15 years of experience leading technology companies at the intersection of AI and healthcare, with full P&L responsibility for fast-growing ventures. He was previously CEO of OmiCure, an AI-driven tumor-profiling platform, and earlier held strategy roles at Roland Berger and AT Kearney. He takes on the role of CEO as Ariana Pharma enters its next phase of growth, adding flexibility in the business model, increasing the value brought to biotech and pharmaceutical partners.

A statement from Thomas Turcat, Chief Executive Officer:

“Being deeply aware of the challenges of drug development,, I have seen firsthand how too many promising programs fail because of suboptimal trial design and an incomplete understanding of complex data. At Ariana Pharma, our mission is to improve the success rate of drug development by combining explainable AI with deep scientific and clinical expertise, delivering insights researchers can trust and act on with confidence.

As I step into this role, my ambition is to scale our technology, embrace the latest advances in AI, and further strengthen the scientific and clinical excellence that sets Ariana apart. As we grow, preserving our collaborative, science-first culture will remain just as important as advancing our technology, because it is our people and the way we work together, that drive innovation and create lasting value for our partners.

Together, we have a unique opportunity to transform how drug development decisions are made, helping our partners move faster, reduce uncertainty, and bring life-changing therapies to patients.”

Media Contact

Amrutha Mahankali
Marketing Manager



Shorter trials ● Smaller Cohorts ● Better Decisions